Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epitestosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SHBG | P04278 | 5/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epitestosterone SCHEMBL4367142 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL14007478 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL13988208 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Testosterone SCHEMBL15756675 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL13988209 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Testosterone SCHEMBL8452 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL11169161 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL13988894 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL21957465 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL22704809 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 786 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096781-A1 | METHODS AND COMPOSITIONS FOR PROVIDING CUSTOMIZED SKIN REGIMENS | VIBRANT HOLDINGS, LLC (US) | 2025-05-08 | — | — | WO | claimed |
| CN-115963199-B | Quantitative detection method and application of steroid hormone in human/animal body fluid | 上海鹿明生物科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119355175-B | Method for non-targeted detection of 86 hormone interferents in aquatic ecosystem, hormone interferent ecological risk evaluation method and optimal control sequencing method | 成都市食品检验研究院 | 2025-04-29 | — | — | CN | claimed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | claimed |
| CN-119355175-A | Method for non-targeted detection of 86 hormone interferents in aquatic ecosystem, hormone interferent ecological risk evaluation method and optimal control sequencing method | 成都市食品检验研究院 | 2025-01-24 | — | — | CN | claimed |
| CN-119125354-A | Method and kit for measuring various steroid hormones in body fluid by liquid chromatography-mass spectrometry technology | 浙江博圣生物技术股份有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118858479-A | Kit for simultaneously detecting 90 steroid hormones and metabolites thereof in urine sample, detection method and sample pretreatment method | 中国疾病预防控制中心环境与健康相关产品安全所 | 2024-10-29 | — | — | CN | claimed |
| EP-4264281-A2 | LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS | F. Hoffmann-La Roche AG (CH) | 2023-10-25 | — | — | EP | claimed |
| US-20230333123-A1 | LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-10-19 | — | — | US | claimed |
| US-20230333122-A1 | INTERFERENCE MONITORING FOR PROVIDING A VERIFIED ANALYTE MEASUREMENT | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-10-19 | — | — | US | claimed |
| WO-2007140380-A2 | TAGGING REAGENTS AND METHODS FOR HYDROXYLATED COMPOUNDS | APPLERA CORPORATION (US) | 2007-12-06 | — | — | WO | claimed |
| US-20030099960-A1 | Administration of epirubicin for use in the treatment of cancer; obtain sample, incubate with antitumor agent, monitor adjustment in glucoronyltransferase activity, evaluate effectiveness antitumor agent | THE UNIVERSITY OF CHICAGO | 2003-05-29 | — | — | US | claimed |
| WO-2002092618-A1 | 17 ALPHA-HYDROXY-4-ANDROSTENE-3-ONE AND THE 14, 15-METHYLENE-DERIVATIVES THEREOF | SCHERING AG (DE) | 2002-11-21 | — | — | WO | claimed |
| WO-2002087552-A2 | ANDROGEN-MEDIATED NEUROPROTECTION AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2002-11-07 | — | — | WO | claimed |
| WO-2002059375-A9 | DETERMINATION OF UGT2B7 GENE POLYMORPHISMS FOR PREDICTING UGT2B7 SUBSTRATE TOXICITY AND FOR OPTIMISING DRUG DOSAGE | UNIV CHICAGO (US) | 2002-10-31 | — | — | WO | claimed |
| US-6432939-B1 | SEXUAL DISORDERS | OETTEL MICHAEL (DE) | 2002-08-13 | — | — | US | claimed |
| WO-2002059375-A2 | DETERMINATION OF UGT2B7 GENE POLYMORPHISMS FOR PREDICTING UGT2B7 SUBSTRATE TOXICITY AND FOR OPTIMISING DRUG DOSAGE | UNIVERSITY OF CHICAGO (US) | 2002-08-01 | — | — | WO | claimed |
| US-20010020002-A1 | Androgen activity antagonists as therapies for anorexia, anorexia nervosa and disorders characterized by a pathologically underweight condition | VELA PHARMACEUTICALS INC. | 2001-09-06 | — | — | US | claimed |
| EP-1024820-A1 | ANDROGEN ACTIVITY ANTAGONISTS AS THERAPIES FOR ANOREXIA, ANOREXIA NERVOSA, AND DISORDERS CHARACTERIZED BY A PATHOLOGICALLY UNDERWEIGHT CONDITION | Janus Pharmaceuticals, Inc. (US) | 2000-08-09 | — | — | EP | claimed |
| WO-1999010003-A1 | ANDROGEN ACTIVITY ANTAGONISTS AS THERAPIES FOR ANOREXIA, ANOREXIA NERVOSA, AND DISORDERS CHARACTERIZED BY A PATHOLOGICALLY UNDERWEIGHT CONDITION | JANUS PHARMACEUTICALS, INC. (US) | 1999-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | AR 161/4885LMNA 3666/4885CYP3A4 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.